Ljubljana center of Europe during EAU 9th Central European meeting

October 15, 2009

Ljubljana, the Slovenian capital, is hosting the EAU 9th Central European Meeting, which will be held on 23 and 24 October. Professor Ciril Oblak (Ljubljana, SI) is chairman of the meeting. "These meetings help to make the differences between Western European and Central European countries in terms of urological treatments smaller", he says. The Cankarjev dom Cultural and Congress Centre is this year's CEM venue.

The scientific programme offers information on a broad range of subjects, including Managing Complications of pelvic radiotherapy, Male incontinence plus a promising debate about 'Prostate cancer: Is active surveillance a valid option?' on Friday 23 October. Saturday 24 October features challenging subjects such as Update on Infections Disease, the state-of-the-art lecture 'Update on Penile Cancer' by Prof P. Nyirady from Budapest (HU) and panel discussions on T3 prostate cancer: Radiotherapy or radical prostatectomy, Radiotherapy and Radical prostatectomy.

Poster viewing sessions on BPH and urinary tract infections, Incontinence, Andrology and Testicular tumours, Benign and Malignant renal diseases and Kidney transplant, Nephrolithiasis and Prostate cancer are organised on both days, with an approximately equal number of posters that were sent in.

The award winners will be chosen on-site by the chairmen of the poster sessions, often Advisory Board members. The awards will be presented at the end of the meeting by Professors Ciril Oblak, Congress President and M. Marberger (Vienna, AT), Chairman EAU Regional Office. The award-winning posters will be displayed in a specifically designated area at the Annual EAU Congress in Barcelona for the duration of the congress.

The EAU's various regional meetings also offer an excellent way for young urologists to present their work and achievements in an international setting. "The regional meetings are intended to develop a platform, where new experimental and clinical work from the region is presented to an international audience. It is the ideal forum for urologists from the region to meet colleagues with similar interests and to develop urological networks within the region," said Professor Michael Marberger.
-end-
All programmes and abstracts of regional meetings will be incorporated into one supplement of European Urology.

The Autumn meeting of the European Society for Residents in Urology (ESRU) - the independent organisation representing European residents and organising residents training, will be organised simultaneously. All residents are invited to be present on Saturday 24 October from 13:00-18:00 hrs.

The EAU 9th CEM is accredited by the EU-ACME (European Urology-Accredited Continuing Medical Education). For more information, please go to http://cem.uroweb.org or mail to regionalmeetings@uroweb.org.

European Association of Urology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.